Pharmacy Grand Rounds

TramaDO or TramaDON’T? Re-evaluating the Role of Tramadol in Pain Management

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

In 1995, the FDA approved tramadol for the indications of moderate to severe pain in adult populations in the United States. The drug was touted by its German manufacturer to provide opioid activity and carry a lower risk of abuse and dependence than other short-acting opioids. Utilization of tramadol has increased significantly with the increased awareness regarding long-term abuse risks of opioid therapy. This presentation will review information regarding the safety and efficacy of tramadol for the treatment of pain and evaluate the claim that tramadol carries a low abuse potential.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Discuss evidence for efficacy of tramadol for indications of acute or chronic pain in adults
2. Describe major safety and pharmacokinetic considerations for the utilization of tramadol
3. Assess the current misuse and abuse potential of tramadol

Session Announcement

Session Slides

FACULTY INFORMATION

Kellyn K. Engstrom, PharmD, MPH
PGY1 Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Kellyn received a Doctor of Pharmacy degree and Master of Public Health degree from the University of Wisconsin-Madison.  She is a current PGY1 Pharmacy Resident at Mayo Clinic Hospital-Rochester with practice interests in emergency medicine, toxicology, and pain management.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Kellyn K. Engstrom, PharmD, MPH
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will not be discussed during this presentation.

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS